12th February 2026, A/Prof Chee L Khoo
When we think about major complications in patients with type 2 diabetes (T2D), we automatically think of an atherosclerotic cardiovascular event. While diabetic kidney disease, diabetic foot disease and retinopathy makes the quality of life miserable the last 5-7 years of their shortened lifespan but it is ASCVD events that kills them.…
27th January 2026, A/Prof Chee L Khoo
We are very familiar with preventing the progression of prediabetes to type 2 diabetes (T2D). Achievement of remission involves multi-component interventions including dietary and physical activity measures and often, pharmacological intervention. Patients with T2D are at heightened cardiometabolic complications. You would think that preventing the progression from prediabetes to diabetes will prevent some of these complications.…
3rd January 2026, A/Prof Chee L Khoo
Women, in general, have a lower cardiovascular (CV) risk because of the “protection” from the oestrogen exposure from puberty onwards. Of course, that “protection” ends when a woman becomes menopausal and indeed, the prevalence of CV events very quickly approaches those of men within a few years. One of the most difficult decisions to make is when to treat elevated lipids in women.…
28th December 2025, A/Prof Chee L Khoo
We discussed the Lancet Commission’s clinical obesity 12 months ago. Clinical obesity is obesity in the presence of a clinical disease (whether complication or co-morbidity). This is why the PBS is funding semaglutide for patients with obesity and established cardiovascular (CV) disease and not obesity on its own. There are many other “diseases” associated with obesity which will be funded by the PBS in the very near future.…
25th December, 2025, A/Prof Chee L Khoo
With increasing prevalence of obesity, type 2 diabetes, hypertension and obstructive sleep apnoea, we are encountering increasing prevalence of atrial fibrillation in our practice. These are the common risk factors which we associate with a higher risk of developing AF. Surprisingly, there is one group which stands out different from the expected groups listed above.…
29th November 2025, A/Prof Chee L Khoo
We all know how complicated that question is – to screen or not to screen for prostate cancer? There are so many questions that we need to answer when we consider that question. We thought we have the answers when a series of clinical trials from Europe, UK and US reported over the last 15 years.…
23rd November 2025, A/Prof Chee L Khoo
Patients used to be given tacit recommendations about lifestyle changes for metabolic dysfunction associated fatty liver disease (MAFLD) because it’s “just a little fat in the liver”. For those of us who have that few patients with those liver as well as non-liver complications, we will remember how horrible these patients fare moving forward.…
11th November, A/Prof Chee L Khoo
Don’t we all hate the onerous restrictions on the PBS Authority criteria to qualify for the PCSK9 therapy. The efficacy of the agents (evolocumab, alirolocumab and inclisran) is well proven in clinical trials (1-3). Only the -mabs have been shown to have cardiovascular (CV) benefits. CV outcomes is yet to be established with inclisiran.…
31st October 2025, A/Prof Chee L Khoo
We have covered the issue of lipoprotein (a) on a number of occasions in the past. We highlighted how the additional atherosclerotic harm in patients with elevated levels. Although lipoprotein (a) lowering agents are yet to hit the market, it is still important to check the levels at least once in all patients as the results may influence your LDL-C targets as well as prompt further cardiovascular investigations.…
31st October 2025, A/Prof Chee L Khoo
The role of aspirin is well established in secondary prevention of cardiovascular events. However, it’s coming up to 10 years since international guidelines specifically recommend against aspirin in primary prevention of CV events (1-3). There have been a number of landmark studies looking at the risk and benefits of aspirin in primary prevention.…
11th October 2025, A/Prof Chee L Khoo
Weekly semaglutide injectable has been around for some years now. Even with my special interest in diabetes and obesity, I am getting confused with all the clinical trials involving semaglutide in patients with obesity with or without diabetes. They all have very innovative acronyms most of them starting with “S” which makes them hard to keep track of.…
29th September 2025, A/Prof Chee L Khoo
I must admit that I have been doing this for many years on an ad hoc basis. I have been screening for helicobacter pylori (HP) infection in patients who need to be on aspirin (primary or secondary prevention of coronary artery disease). This isn’t what is recommended in any cardiovascular (CV) disease guidelines until recently but the evidence is not robust.…